Efficacy, Safety And Tolerability Of Bhv-7000 In Subjects With Refractory Focal Onset Epilepsy- Rise 2
Posted Date: Apr 24, 2024
- Investigator: Michael Privitera
- Specialties:
- Type of Study: Drug
This is a Phase 2/3, global, multicenter, randomized, double-blind, placebo-controlled 3-arm study designed to assess the efficacy and safety of BHV-7000 in subjects with refractory focal onset epilepsy who are on a stable epilepsy treatment regimen with at least 1 and up to 3 ASM(s).
Criteria:
Null
Keywords:
Bhv7000-302, Anti-Epiletic
For More Information:
Patrick Newell
513-558-0115
newellpk@ucmail.uc.edu